Neuron Bio, SA filed its Annual on May 05, 2015 for the period ending Dec 31, 2014. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
2017 | Neuron BioLabs, S.L. cancelled the acquisition of diagnostics operations, R&D services and patents of Alzheimer's disease from Neuron Bio, SA. | CI |
2017 | Neol Biosolutions Seeks Investors | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 51.94L | |
+8.63% | 11TCr | |
+13.17% | 11TCr | |
-12.76% | 2.22TCr | |
-3.99% | 2.13TCr | |
-7.19% | 1.75TCr | |
-39.93% | 1.72TCr | |
+6.67% | 1.41TCr | |
+33.90% | 1.22TCr | |
-28.60% | 783.09Cr |
- Stock Market
- Equities
- NEU Stock
- News Neuron Bio, S.A.
- Neuron Bio, SA Auditor Raises 'Going Concern' Doubt